Clarity Pharmaceuticals Ltd. · ASX:CU6
Clarity Pharmaceuticals — Canaccord Drug and Device Conference 2025
12 slides from Clarity Pharmaceuticals's conference presentation, October 2025
Slide 1: Canaccord Drug and Device Conference
Canaccord Drug and Device Conference October 2025 Dr Alan Taylor, Executive Chairperson
Slide 2: Disclaimer
Disclaimer Introduction This presentation has been prepared by Clarity Pharmaceuticals Ltd (ACN 143 005 341) (Clarity or the Company) No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking and contains summary information about Clarity and t
Slide 3: Clarity – The Copper Theranostics Company
Clarity – The Copper Theranostics Company SAR Technology Targeted Copper Theranostics are the next- generation disruptive platform in Radioisotope radiopharmaceuticals that employ the “perfect Copper isotopes for Positron Emission pairing” of copper-64 (64Cu) and copper-67 (67Cu) Tumour Tomography (
Slide 4: SAR-bisPSMA
SAR-bisPSMA Two Proprietary Positions Dual PSMA targeting What's all the hype? 1. Composition of matter on chelator Unique dimer with two that securely holds copper targeting molecules leads 2. Composition of matter on SAR- to increased tumour uptake bisPSMA dual targeting molecule Precision Targeti
Slide 5: Monomer vs Dimer
Monomer vs Dimer • Pluvicto® Superior performance of bisPSMA compared • SAR-bisPSMA • Pylarify® to monomer PSMA • Posluma® • 68Ga-PSMA-11 • 177Lu-PNT2002 Significantly better binding and internalisation 5 Zia et al., 2019. Ang.Chem
Slide 6: SAR-bisPSMA
SAR-bisPSMA SECuRE - Phase I/IIa • Cohort Expansion (Phase II) ongoing at Targets the Prostate Specific Membrane Antigen 8 GBq dose level (enzalutamide combination allowed) (PSMA), present in the majority of prostate cancers • Dose Escalation (Phase I) successfully completed • Fast-Track Designation
Slide 7: Next-generation SAR-bisPSMA diagnostic is coming
Next-generation SAR-bisPSMA diagnostic is coming Current PSMA PET imaging market for the US is approximately US$2 billion per year. Improved lesion uptake and detection by 64Cu-SAR- bisPSMA aims to overcome the significant low sensitivity issues of first-generation PSMA PET agents and displace appro
Slide 8: SAR-bisPSMA is safe and effective in detecting tumours in prostate cancer patients
SAR-bisPSMA is safe and effective in detecting tumours in prostate cancer patients Clinicians reported they would change their treatment plan in approximately 50% of patients due to 64Cu-SAR-bisPSMA scans, signalling a potential material improvement in patient care Patients with negative/equivocal S
Slide 9: Higher uptake and contrast in lesions on next-day imaging and detection of lesions in the 2-mm range
Higher uptake and contrast in lesions on next-day imaging and detection of lesions in the 2-mm range SUVmean and SUVmax in lesions TBR of lesions detected by detected by 64Cu-SAR-bisPSMA 64Cu-SAR-bisPSMA 30 150 Mean SUVmean and Mean TBR of lesions SUVmax in lesions 25 20 100 15 10 50 5 0 0 SUVmean S
Slide 10: 64Cu-SAR-bisPSMA identifies lesions months before currently approved PSMA PET agents
64Cu-SAR-bisPSMA identifies lesions months before currently approved PSMA PET agents Number of lesions identified by 64Cu-SAR-bisPSMA detects lymph node missed by 68Ga-PSMA-11 64Cu-SAR-bisPSMA and SOC PSMA agents (SOC PET performed ~6 months later) 60 53 64Cu-SAR-bisPSMA Next-day imaging 50 Prostate
Slide 11: Co-PSMA IIT achieves primary endpoint: Head-to-head trial of 64Cu-SAR-bisPSMA vs. 68Ga-PSMA-11 in low-PSA BCR
Co-PSMA IIT achieves primary endpoint: Head-to-head trial of 64Cu-SAR-bisPSMA vs. 68Ga-PSMA-11 in low-PSA BCR Patient population 64Cu-SAR-bisPSMA (200 MBq) Screening Follow-up • Prior radical prostatectomy (confirmed 68Ga-PSMA-11 adenocarcinoma of PC) Same-day imaging Next-day imaging Salvage Rx, bi
Slide 12: Thank you
Thank you Contact details Dr Alan Taylor Executive Chairperson E: alan.taylor@claritypharm.com
Clarity Pharmaceuticals — Canaccord Drug and Device Conference 2025 on 6ix